Efficacy of pioglitazone on glycemic control and carotid intima-media thickness in type 2 diabetes patients with inadequate insulin therapy

Journal of Diabetes Investigation

Volumn 2, Issue 1, 2011, Pages 56-62

  Yasunari, Eisuke ^a   Takeno, Kageumi ^a   Funayama, Hideaki ^a   Tomioka, Setsuko ^a   Tamaki, Motoyuki ^a   Fujitani, Yoshio ^a   Kawamori, Ryuzo ^a   Watada, Hirotaka ^a   Hirose, Takahisa ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Insulin therapy; Pioglitazone

Indexed keywords

ADIPONECTIN; C PEPTIDE; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; B SCAN; CAROTID ATHEROSCLEROSIS; CLINICAL ARTICLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; INTIMA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 79960528359     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00064.x     Document Type: Article

References (25)

1. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
2. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
3. Pftzner A, Marx N, Lbben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the Pioneer study. J Am Coll Cardiol 2005; 45: 1925-1931.
4. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
5. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111: 2525-2531.
6. Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004; 53: 1382-1386.
7. Koshiyama H, Shimono D, Kuwamura N, et al. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456.
8. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572-2581.
9. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573.
10. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
11. Schwartz S, Raskin P, Fonseca V, et al. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 1998; 338: 861-866.
12. Buse JB, Gumbiner B, Mathias NP, et al. Troglitzzone use in insulin-treated type 2 diabetic patients. Diabetes Care 1998; 21: 1455-1461.
13. Fonseca V, Foyt HL, Shen K, et al. Long-term effects of troglitazone. Open-label extension studies in type 2 diabetic patients. Diabetes Care 2000; 23: 354-359.
14. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-1232.
15. Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 2005; 27: 554-567.
16. Davidson JA, Perez A, Zhang J, The Pioglitazone 343 Study Group. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes Obes Metab 2006; 8: 164-174
17. Berhanu P, Perez A, Yu S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Diabetes Obes Metab 2007; 9: 512-520.
18. Strowig SM, Raskin P. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Diabetes Obes Metab 2005; 7: 633-641.
19. Mitsuhashi N, Tanaka Y, Kubo S, et al. Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients. Endocr J 2004; 51: 545-550.
20. Mita T, Watada H, Uchino H, et al. Association of C-reactive protein with early-stage carotid atherosclerosis in Japanese patients with early-state type 2 diabetes mellitus. Endocr J 2006; 53: 693-698.
21. Mita T, Watada H, Shimizu T, et al. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Atheroscler Thromb Vasc Biol 2007; 27: 2456-2462.
22. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277: 25863-25866.
23. Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002; 277: 37487-37491.
24. Rosenstock J, Emhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes a randomized, placebo controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251-257.
25. Mudliar S, Chang AR, Henry RR. Thiazolinediones, peripheral edema, and type 2 diabetes incidence, pathophysiology and clinical implications. Endocr Pract 2003; 9: 406-416.